leprosy
Conditions
Interventions
case (DHS):Non
control1 (leprosy without DHS):Non
Sponsors
Institute of Dermatology,chinese Acadeemy of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 68 Years
Inclusion criteria
Inclusion criteria: 1.1 Criteria for enrollment into DHS group; 1) Chinese active leprosy patients or cured patients; 2) Unrestricted gender and age; 3) Must accept dapsone, rifampin, and/or clofazimine triple therapy; in the first 8 weeks of treatment, must show signs and symptoms of DHS, as defined by Richardus and Smiths DHS diagnostic criteria; 4) Must have complete medical records of DHS progression, treatment, and follow-up; 5) Voluntary participation and signing of written informed consents; All of the above criteria for enrollment must be met. 1.2 Criteria for enrollment of dapsone-tolerated leprosy patients; 1) Chinese active leprosy patients or cured patients; 2) Unrestricted gender and age; 3) Good cognitive capacity and memory to provide sufficiently detailed treatment history and/or medical records; 4) Must have used dapsone for more than 8 weeks in the past 3 years without developing signs and symptoms of DHS; 5) Voluntary participation and signing of written informed consents. All of the above criteria for enrollment must be met. 1.3 Criteria for enrollment of healthy participants 1) Chinese ethnicity who are residents of the same provinces as the studys leprosy patients; 2) Age and gender matched with patients in DHS and dapsone-tolerated leprosy patient groups; 3) No history of leprosy; no history of severe systemic disease; 3) Voluntary participation and affirmed oral informed consents; All of the above criteria for enrollment must be met.
Exclusion criteria
Exclusion criteria: Criteria for exclusion from all study groups 1) Non-Chinese ethnicity; 2) Patients whose blood samples cannot be collected; 3) Patients who are at least second degree blood relatives to any other study patient; 4) Drug hypersensitivity symptoms ascribed to any other drug given simultaneously; 5) Severe hepatopathy, hematologic disorder, or other systemic diseases history which may affect DHS evaluation. If there was any of all the criteria above, he or she cannot be enrolled in this study.
Countries
China
Contacts
Public ContactHongsheng Wang
Outcome results
None listed